Aerie Pharmaceuticals IncのBeta
Aerie Pharmaceuticals IncのBetaは何ですか。
Aerie Pharmaceuticals IncのBetaは0.00です。
Betaの定義は何ですか。
BETAは、株式が市場全体よりも多かれ少なかれ揮発性であるかどうかを示します。 1未満のベータは株式が市場よりも揮発性が低いことを示し、1より大きいベータは株式がより揮発性であることを示します。ボラティリティは、平均値周辺の価格の変動として測定されます。
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
NASDAQのセクタHealth CareにおけるBetaの企業と比べるAerie Pharmaceuticals Inc
Aerie Pharmaceuticals Incは何をしますか。
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Incと類似のbeta
- Vision Marine TechnologiesのBetaは0.00です。
- Ely Gold RoyaltiesのBetaは0.00です。
- Glacier Lake ResourcesのBetaは0.00です。
- Magnum Mining and ExplorationのBetaは0.00です。
- Africa Opportunity FundのBetaは0.00です。
- Fulcrum Utility ServicesのBetaは0.00です。
- Aerie Pharmaceuticals IncのBetaは0.00です。
- GullewaのBetaは0.00です。
- S.A.L. SteelのBetaは0.00です。
- Andina Acquisition IIIのBetaは0.00です。
- Andina Acquisition IIIのBetaは0.00です。
- Brilliant AcquisitionのBetaは0.00です。
- IndokemのBetaは0.00です。